Biomarkers · Cardiac & Hemodynamics
Pericardial Fat Volume
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death1.34×per SD increment in pericardial fat area (95% CI 1.01–1.78) · 343 community-dwelling older adults (mean age 67) without CVD, Rancho Bernardo Study, chest CT 2001-02
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in Pericardial Fat Volume, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
Things that worsen it
| Type | Condition or exposure | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Pioglitazone 30 mg orally daily for 24 weeks in men with type 2 diabetes without structural heart disease | Pericardial fat volume rose from 30.5 to 33.1 mL with pioglitazone vs 29.2 to 29.6 mL with metformin at 24 weeks (between-group P = 0.02) | RCT | Jonker JT, et al. J Clin Endocrinol Metab. 2010. Pioglitazone compared with… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Coronary atherosclerotic stenosis · patients with atherosclerotic lesions on MDCT vs without | +57 cm3 | coronary atherosclerosis present (308 +/- 96 cm3) vs absent (251 +/- 93 cm3) · Korean adults undergoing multidetector-row CT (Korean Atherosclerosis Study 2) | cross sectional · PMID 20948524 |